ALZN (Alzamend Neuro Inc.) stock: $1.41, $6.8M market cap, $7.6M cash, -$0.8M EV, $9.2M fully diluted market cap. Next expected readout: Dec-26. Lead program: AL001 (Bipolar I Disorder), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Our primary target, Alzheimer’s, is among the most-feared diseases (second only to cancer) among Americans, according to a 2024 Center for Disease Control and Prevention survey. Alzheimer’s is also the fifth leading cause of death (in 2024) in the United States (the “U.S.”) according to a 2026 report from the Alzheimer’s Association, a nonprofit that funds research.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships University of South Florida (Licensor): exclusive worldwide licenses for AL001; 4.5% royalties on net sales. Massachusetts General Hospital / Harvard Medical School: partnership to conduct five Phase II imaging ("Lithium in Brain") trials
Indications
Alzheimer's disease(Phase 2)
Bipolar disorder (BD)(Phase 2)
Major depressive disorder (MDD)(Phase 2)
PTSD(Phase 2)
Catalysts
— fourth quarter of 2026
— fourth quarter of 2026
Status note Lead product; ionic cocrystal of lithium, oral capsule. Phase IIA MAD study completed March 2023. Phase II BD "Lithium in Brain" study initiated March 2026; MDD/PTSD studies expected to commence Q4 2026, Alzheimer's study Q1 2027.
Partnerships Licensor: Standard Exclusive License Agreement with Sublicensing Terms (May 1, 2016), royalty-bearing exclusive worldwide license
Indications
Mild to moderate dementia of the Alzheimer's type(Phase 2)
Catalysts
— second quarter of 2027
Status note Phase I/IIA trial initiated April 3, 2023; IND submitted September 2022 ("study may proceed" October 31, 2022). Trial not terminated but paused pending replacement CRO; restart expected Q2 2027.
Per-asset detail extracted from the 10-Q filed 2026-09-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.